# Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

> **NCT04488978** · PHASE2 · COMPLETED · sponsor: **Handok Inc.** · enrollment: 440 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Irbesartan/Amlodipine

## Key facts

- **NCT ID:** NCT04488978
- **Lead sponsor:** Handok Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-21
- **Primary completion:** 2021-11-09
- **Final completion:** 2021-11-09
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04488978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04488978, "Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04488978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*